Nanobiotix S.A. Overview
Pro stress-test →Nanobiotix S.A. operates as a clinical-stage biotechnology company focused on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.
Strategic Profile
Pro stress-test →Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company in 2023. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. This dual partnership strategy positions Nanobiotix to maximize market reach across geographies while leveraging J&J's global oncology capabilities.
Competitive Landscape
Pro stress-test →Nanobiotix operates in the immuno-oncology and radiotherapy enhancement space, competing with other nanoparticle-based cancer therapies and checkpoint inhibitor combinations. The differentiation lies in its physics-based approach using hafnium oxide nanoparticles activated by radiotherapy rather than purely immunological mechanisms. Competitors include companies developing alternative radiosensitizers, immunotherapy combinations, and precision oncology solutions, though Nanobiotix's first-in-class positioning in nanoradiotherapy provides competitive advantage.
Industry Context
Nanobiotix S.A. operates in Nanotherapeutic oncology platforms.
Key facts
Founded: 2003 · Headquarters: Paris, France · Employees: N/A · Revenue: N/A · Market cap: N/A